Abstract 380P
Background
Globally, there are roughly 476 million indigenous peoples in 90 nations worldwide, representing a wide range of cultures, dialects, and spirits. India has the world's second-highest concentration of tribal people after African countries. Spread across 705 tribes accounting for 8.6% of the country’s population, over 104 million tribal people live; making India home to numerous tribes with diverse origins, customs, and societal practices. Government of India have identified Primitive tribal communities on the basis of their pre-agricultural level of technology, extremely low level of literacy, and small, stagnant, or diminishing population. This epidemiological cross- sectional study was designed to assess the prevalence of oral cancer and its awareness among Irula tribes of South India.
Methods
A cross sectional descriptive study was conducted among 200 Irula tribes using a pretested Questionnaire, which included demographic information, tobacco habits, its frequency, and cancer awareness. Oral examination to assess oral cancer was done by a single examiner. SPSS version 21 was used to analyse the collected data.
Results
The findings revealed that 87% of the 200 study participants had no formal education and 38% had never visited a dentist. 64.5% practised indigenous brushing. There were 52% of oral mucosal lesions and 6% of malignant oral tumours found. This community had a very high prevalence of periodontal disease, tobacco chewing, and deeply ingrained beliefs and customs about dentition and dental treatment. The prevalence of oral mucosal lesions in the study population was due to tobacco use and a lack of knowledge about the harmful effects of the products used.
Conclusions
Although the problems associated with smoking and chewing tobacco are extensively documented in the literature, it is worrying that this indigenous group is not aware of the consequences. The public should be made aware of these concerns, especially those in high-risk groups, according to health specialists.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract